"The pharmaceutical sector is challenged by a series of issues pertaining to clinical trials—patient recruitment, ensuring the safety of human subjects, maintaining consistency and reliability in data, and reducing costs. Additionally, it is commonly observed that trial progressions don’t coincide with the projections made by the CROs, and hence, sponsors lose potential future revenues. Empowering pharmaceutical firms to effectively address these challenges and navigate the changing landscape of clinical trials is US-based CRO Cromos Pharma. The company provides its clients with quintessential services that help them reduce costs, shorten timelines, and lower rates of audit findings.
Cromos Pharma exercises a multi-layer approach towards quality assurance, where it identifies the specific threats and predicts potential recurring risks that might arise during a clinical trial. Considering that every clinical trial is unique, the company’s continuous risk monitoring is the lynchpin of its success. Cromos Pharma constantly assesses and monitors for threats throughout the trial, and it often doesn’t budget them into its proposals.
“It is the constant re-evaluation that really enables us to find the weak links within a clinical trial. Rather than being reactive to problems, we remain proactive and prevent problems before they can occur,” says Dr. Vlad Bogin.
Cromos Pharma upholds its commitment to ensuring the success of a clinical trial with its “No Patients - No Payment” risk-sharing initiative. While determining or suggesting trial venues, Cromos Pharma discusses the requirements of the clinical trials with the sponsors and assesses the technical capabilities of various locations and the specific procedures they cater to. The company simultaneously executes risk assessment programs and practices a strong visibility process by remaining upfront about potential difficulties. It then prepares a customized proposal and provides an anticipated rate of patient recruitment for the trial. If the sponsor agrees with the proposal, Cromos Pharma memorializes the recruitment projections in the MSA, and if it underdelivers, it is penalized financially—a scenario unheard of in the industry, which consolidates Cromos Pharma’s claims regarding quality assurance and management.
Owing to the presence of large, specialized centers dealing with specific diseases, the company swiftly recruits patients without compromising the quality of data.
“Some sponsors are still unaware that our data is FDA, EMA, ICH GCP compliant and admissible, and on par, if not of higher quality than in Western Europe and in North America. But for those who know, it’s one of the prime factors that attracts sponsors to partner with us,” continues Vlad.
The company’s teams of seasoned and motivated experts, investigators, and agents forge strong bonds with its sponsors and become their partners to ensure efficient implementation of quality assurance protocols and seamless execution of the trials."
Cromos Pharma is pleased to share news about our latest project - an international double-blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI). The trial involving patients in the US and in Russia will investigate how a biologic RPH-104 developed by R-Pharm can reduce an acute inflammatory response after myocardial infarction and lead to improved outcomes for STEMI patients.
Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.
March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.